Cargando…
The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
Background: Epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) combined with chemotherapy in patients with RAS (rat sarcoma viral oncogene homolog) wild-type metastatic colorectal cancer (mCRC) can alleviate and stabilize the disease, effectively prolong the progression-free surviv...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006990/ https://www.ncbi.nlm.nih.gov/pubmed/35433839 http://dx.doi.org/10.3389/fmolb.2022.870395 |
_version_ | 1784686768950345728 |
---|---|
author | Yuan, Meiqin Wang, Zeng Lv, Wangxia Pan, Hongming |
author_facet | Yuan, Meiqin Wang, Zeng Lv, Wangxia Pan, Hongming |
author_sort | Yuan, Meiqin |
collection | PubMed |
description | Background: Epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) combined with chemotherapy in patients with RAS (rat sarcoma viral oncogene homolog) wild-type metastatic colorectal cancer (mCRC) can alleviate and stabilize the disease, effectively prolong the progression-free survival (PFS) and overall survival (OS), and improve the overall response rate (ORR), which is the first-line treatment standard scheme for RAS wild-type mCRC currently. However, whether anti-EGFR mAb can be used for the maintenance treatment after the first-line treatment of mCRC remains controversial. We reviewed the recent studies on anti-EGFR mAb. The contents include five parts, introduction, anti-EGFR mAb in mCRC and its status in first-line therapy, establishment of the maintenance treatment pattern after the standard first-line treatment for mCRC, research progress of anti-EGFR mAb in mCRC maintenance therapy, and conclusion. More studies support the maintenance treatment of anti-EGFR mAb, but some researchers raise the problems about high cost and drug resistance. Despite lack of the maintenance evidence of anti-EGFR mAb, especially lack of large-scale phase III prospective clinical trials, with the emergence of new evidence and more accurate screening of treatment-dominant groups, maintenance therapy with anti-EGFR mAb monotherapy or anti-EGFR mAb combined with fluorouracil-based schemes after first-line chemotherapy combined with anti-EGFR mAb therapy might strive for more treatment opportunities, optimize treatment strategies and prolong treatment continuity, and finally, lead to more survival benefit for suitable patients. |
format | Online Article Text |
id | pubmed-9006990 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90069902022-04-14 The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy Yuan, Meiqin Wang, Zeng Lv, Wangxia Pan, Hongming Front Mol Biosci Molecular Biosciences Background: Epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) combined with chemotherapy in patients with RAS (rat sarcoma viral oncogene homolog) wild-type metastatic colorectal cancer (mCRC) can alleviate and stabilize the disease, effectively prolong the progression-free survival (PFS) and overall survival (OS), and improve the overall response rate (ORR), which is the first-line treatment standard scheme for RAS wild-type mCRC currently. However, whether anti-EGFR mAb can be used for the maintenance treatment after the first-line treatment of mCRC remains controversial. We reviewed the recent studies on anti-EGFR mAb. The contents include five parts, introduction, anti-EGFR mAb in mCRC and its status in first-line therapy, establishment of the maintenance treatment pattern after the standard first-line treatment for mCRC, research progress of anti-EGFR mAb in mCRC maintenance therapy, and conclusion. More studies support the maintenance treatment of anti-EGFR mAb, but some researchers raise the problems about high cost and drug resistance. Despite lack of the maintenance evidence of anti-EGFR mAb, especially lack of large-scale phase III prospective clinical trials, with the emergence of new evidence and more accurate screening of treatment-dominant groups, maintenance therapy with anti-EGFR mAb monotherapy or anti-EGFR mAb combined with fluorouracil-based schemes after first-line chemotherapy combined with anti-EGFR mAb therapy might strive for more treatment opportunities, optimize treatment strategies and prolong treatment continuity, and finally, lead to more survival benefit for suitable patients. Frontiers Media S.A. 2022-03-30 /pmc/articles/PMC9006990/ /pubmed/35433839 http://dx.doi.org/10.3389/fmolb.2022.870395 Text en Copyright © 2022 Yuan, Wang, Lv and Pan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Molecular Biosciences Yuan, Meiqin Wang, Zeng Lv, Wangxia Pan, Hongming The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy |
title | The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy |
title_full | The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy |
title_fullStr | The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy |
title_full_unstemmed | The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy |
title_short | The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy |
title_sort | role of anti-egfr monoclonal antibody in mcrc maintenance therapy |
topic | Molecular Biosciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006990/ https://www.ncbi.nlm.nih.gov/pubmed/35433839 http://dx.doi.org/10.3389/fmolb.2022.870395 |
work_keys_str_mv | AT yuanmeiqin theroleofantiegfrmonoclonalantibodyinmcrcmaintenancetherapy AT wangzeng theroleofantiegfrmonoclonalantibodyinmcrcmaintenancetherapy AT lvwangxia theroleofantiegfrmonoclonalantibodyinmcrcmaintenancetherapy AT panhongming theroleofantiegfrmonoclonalantibodyinmcrcmaintenancetherapy AT yuanmeiqin roleofantiegfrmonoclonalantibodyinmcrcmaintenancetherapy AT wangzeng roleofantiegfrmonoclonalantibodyinmcrcmaintenancetherapy AT lvwangxia roleofantiegfrmonoclonalantibodyinmcrcmaintenancetherapy AT panhongming roleofantiegfrmonoclonalantibodyinmcrcmaintenancetherapy |